Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aggression Following TBI: Effectiveness of Risperidone (AFTER) – feasibility RCT
2015-000641-23Phase 4Completed
- Sponsor
- Central and North West London NHS Foundation Trust
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of risperidone in Aggression (not a disease; see rationale) and agitation (2 arms), sponsored by Central and North West London NHS Foundation Trust. Primary endpoints: Standard deviation of MOAS at 12 weeks and change from baseline, Irritability score standard deviation (IRQ) and 2 more. Started Feb 2019; status: completed.
02
Drugs
risperidone
03
Conditions
Aggression (not a disease; see rationale)agitation
Beyond the preview
Go deeper on 2015-000641-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000641-23.